Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Trastuzumab
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Herceptin 150mg pdr for concentrate for inf vials
0801050ADBBAAAA
|
Herceptin | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Herceptin 600mg/5ml solution for injection vials
0801050ADBBABAB
|
Herceptin | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Herzuma 150mg pdr for concentrate for inf vials
0801050ADBEAAAA
|
Herzuma | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Herzuma 420mg pdr for concentrate for inf vials
0801050ADBEABAE
|
Herzuma | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Kadcyla 100mg pdr for concentrate for inf vials
0801050ADBCAAAC
|
Kadcyla | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Kadcyla 160mg pdr for concentrate for inf vials
0801050ADBCABAD
|
Kadcyla | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Kanjinti 150mg pdr for concentrate for inf vials
0801050ADBFAAAA
|
Kanjinti | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Kanjinti 420mg pdr for concentrate for inf vials
0801050ADBFABAE
|
Kanjinti | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Ogivri 150mg pdr for concentrate for inf vials
0801050ADBIABAA
|
Ogivri | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Ogivri 420mg pdr for concentrate for inf vials
0801050ADBIAAAE
|
Ogivri | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Ontruzant 150mg pdr for concentrate for inf vials
0801050ADBDAAAA
|
Ontruzant | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Trastuzumab 150mg powder for solution for infusion vials
0801050ADAAAAAA
|
Trastuzumab | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Trastuzumab 420mg powder for solution for infusion vials
0801050ADAAAEAE
|
Trastuzumab | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Trastuzumab 600mg/5ml solution for injection vials
0801050ADAAABAB
|
Trastuzumab | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Trastuzumab 60mg powder for solution for infusion vials
0801050ADAAAFAF
|
Trastuzumab | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Trastuzumab emtansine 100mg inf vials
0801050ADAAACAC
|
Trastuzumab | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Trastuzumab emtansine 160mg inf vials
0801050ADAAADAD
|
Trastuzumab | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Trazimera 150mg pdr for concentrate for inf vials
0801050ADBGAAAA
|
Trazimera | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Trazimera 420mg pdr for concentrate for inf vials
0801050ADBGABAE
|
Trazimera | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Zercepac 150mg pdr for concentrate for inf vials
0801050ADBHAAAA
|
Zercepac | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Zercepac 420mg pdr for concentrate for inf vials
0801050ADBHACAE
|
Zercepac | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Zercepac 60mg pdr for concentrate for inf vials
0801050ADBHABAF
|
Zercepac | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.